TickerFacts.

Candel Therapeutics, Inc. (CADL): EPS (Diluted)

Annual figures by period end, from SEC filings.

-$0.72
Year ended 2025-12-31
2021-12-31: -$1.912022-12-31: -$0.652023-12-31: -$1.312024-12-31: -$1.742025-12-31: -$0.72-$0.72
2021-12-31 EPS (Diluted) (USD per share) 2025-12-31
Period endedEPS (Diluted)Change YoYSource filing
2025-12-31-$0.72n/m2026-03-12, From 2025-01-01
2024-12-31-$1.74n/m2026-03-12, From 2024-01-01
2023-12-31-$1.31n/m2025-03-13, From 2023-01-01
2022-12-31-$0.65n/m2024-03-28, From 2022-01-01
2021-12-31-$1.91n/a2023-03-30, From 2021-01-01

EPS (Diluted) at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEPS (Diluted)Change YoY
Candel Therapeutics, Inc. (CADL)2025-12-31-$0.72n/m
Acumen Pharmaceuticals, Inc. (ABOS)2025-12-31-$2.00n/m
Kalaris Therapeutics, Inc. (KLRS)2025-12-31-$2.85n/m
Pelthos Therapeutics Inc. (PTHS)2025-12-31-$23.04n/m
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31-$3.43n/m
Palisade Bio, Inc. (PALI)2025-12-31-$0.30n/m
Humacyte, Inc. (HUMA)2025-12-31-$0.26n/m
Zura Bio Ltd (ZURA)2025-12-31-$1.06n/m
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$0.28n/m

Compare CADL, ABOS, KLRS, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗